{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T18:52:42Z","timestamp":1774464762353,"version":"3.50.1"},"reference-count":64,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI141439"],"award-info":[{"award-number":["R01AI141439"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    Aspergillosis is a life-threatening fungal infection that primarily affects the lungs of immunocompromised individuals, including those living with human immunodeficiency virus (HIV), and is associated with mortality rates exceeding 50%. The infection is predominantly caused by\n                    <jats:italic>Aspergillus fumigatus<\/jats:italic>\n                    , a pathogen that has become increasingly difficult to treat due to the emergence of azole-resistant strains. Although azoles have traditionally served as first-line antifungals, the rise in resistance has necessitated broader use of amphotericin B (AmB), a polyene agent whose clinical utility is limited by its considerable toxicity. To address this therapeutic challenge, we screened a library of 618 antiviral compounds to identify agents that could synergize with AmB and enhance its antifungal efficacy. An initial screen identified 18 compounds that enhanced the antifungal activity of AmB. From this hit set, we prioritized the two FDA-approved HIV drugs, cobicistat and elvitegravir, as promising lead candidates. When combined with AmB, both compounds exhibited potent synergistic activity against\n                    <jats:italic>A. fumigatus<\/jats:italic>\n                    and other clinically relevant\n                    <jats:italic>Aspergillus<\/jats:italic>\n                    species, with FICI values &lt;0.5 in over 90% of isolates tested. To further evaluate the breadth of this synergy, the assay was extended to include\n                    <jats:italic>A. brasiliensis, A. flavus, A. niger<\/jats:italic>\n                    , and\n                    <jats:italic>A. terreus<\/jats:italic>\n                    . Synergistic interactions were observed in three of the four species tested, while the combination displayed indifference against\n                    <jats:italic>A. flavus<\/jats:italic>\n                    . In time-kill assays, both combinations demonstrated sustained fungistatic effects over 48 hours and significantly impaired hyphal development as early as 16 hours, indicating early disruption of fungal growth. Additionally, both cobicistat and elvitegravir significantly enhanced the antibiofilm activity of AmB, reducing biofilm biomass by over 60% when combined with sub-inhibitory AmB concentrations. These combinations also disrupted mature biofilms, achieving up to 80% eradication, a substantial improvement over AmB alone. These findings highlight the potential of these drug combinations as promising treatment options for aspergillosis, leveraging already approved therapies.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0344286","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T17:30:32Z","timestamp":1774459832000},"page":"e0344286","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Synergistic antifungal activity of antiretrovirals with amphotericin B against Aspergillus species"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0249-5073","authenticated-orcid":true,"given":"Ammar A.","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ehab A.","family":"Salama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0939-0458","authenticated-orcid":true,"given":"Mohamed N.","family":"Seleem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"4","key":"pone.0344286.ref001","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1111\/brv.12510","article-title":"Fungal evolution: major ecological adaptations and evolutionary transitions","volume":"94","author":"MA Naranjo\u2010Ortiz","year":"2019","journal-title":"Biological Reviews"},{"issue":"19","key":"pone.0344286.ref002","article-title":"Fungal pathogens","volume":"30","author":"S Sun","year":"2020","journal-title":"Curr Biol"},{"issue":"5","key":"pone.0344286.ref003","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.immuni.2015.10.023","article-title":"Immune interactions with pathogenic and commensal fungi: A two-way street","volume":"43","author":"DM Underhill","year":"2015","journal-title":"Immunity"},{"issue":"7","key":"pone.0344286.ref004","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(23)00692-8","article-title":"Global incidence and mortality of severe fungal disease","volume":"24","author":"DW Denning","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"pone.0344286.ref005","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41564-022-01112-0","article-title":"Evolution of the human pathogenic lifestyle in fungi","volume":"7","author":"A Rokas","year":"2022","journal-title":"Nat Microbiol"},{"issue":"3","key":"pone.0344286.ref006","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"TJ Walsh","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"3","key":"pone.0344286.ref007","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1128\/CMR.00055-08","article-title":"Pathogenesis of Aspergillus fumigatus in invasive aspergillosis","volume":"22","author":"TR Dagenais","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"pone.0344286.ref008","article-title":"Clinical risk factors for invasive aspergillosis","author":"JW Baddley","year":"2011","journal-title":"Med Mycol"},{"issue":"2","key":"pone.0344286.ref009","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/1751-7915.12367","article-title":"Ecology of aspergillosis: Insights into the pathogenic potency of Aspergillus fumigatus and some other Aspergillus species","volume":"10","author":"C Paulussen","year":"2017","journal-title":"Microb Biotechnol"},{"issue":"1","key":"pone.0344286.ref010","doi-asserted-by":"crossref","first-page":"2172264","DOI":"10.1080\/21505594.2023.2172264","article-title":"Pathogenicity and virulence of Aspergillus fumigatus","volume":"14","author":"K Earle","year":"2023","journal-title":"Virulence"},{"issue":"1","key":"pone.0344286.ref011","article-title":"Reducing Aspergillus fumigatus Virulence through Targeted Dysregulation of the Conidiation Pathway","volume":"11","author":"JIP Stewart","year":"2020","journal-title":"mBio"},{"issue":"6","key":"pone.0344286.ref012","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1182\/blood-2003-06-2186","article-title":"Interactions of Aspergillus fumigatus with endothelial cells: Internalization, injury, and stimulation of tissue factor activity","volume":"103","author":"LM Lopes Bezerra","year":"2004","journal-title":"Blood"},{"issue":"11","key":"pone.0344286.ref013","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1128\/AAC.00234-08","article-title":"Aspergillus fumigatus forms biofilms with reduced antifungal drug susceptibility on bronchial epithelial cells","volume":"52","author":"MJ Seidler","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"pone.0344286.ref014","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1007\/s00018-020-03736-z","article-title":"Mechanisms of fungal dissemination","volume":"78","author":"AB Strickland","year":"2021","journal-title":"Cell Mol Life Sci"},{"key":"pone.0344286.ref015","doi-asserted-by":"crossref","first-page":"517529","DOI":"10.1155\/2012\/517529","article-title":"Hyphal growth in human fungal pathogens and its role in virulence","volume":"2012","author":"A Brand","year":"2012","journal-title":"Int J Microbiol"},{"key":"pone.0344286.ref016","doi-asserted-by":"crossref","first-page":"528521","DOI":"10.1155\/2012\/528521","article-title":"Fungal biofilm resistance","volume":"2012","author":"G Ramage","year":"2012","journal-title":"Int J Microbiol"},{"issue":"1","key":"pone.0344286.ref017","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41522-022-00347-3","article-title":"Filamentous fungal biofilms: Conserved and unique aspects of extracellular matrix composition, mechanisms of drug resistance and regulatory networks in Aspergillus fumigatus","volume":"8","author":"S Liu","year":"2022","journal-title":"NPJ Biofilms Microbiomes"},{"issue":"1","key":"pone.0344286.ref018","first-page":"2","article-title":"Biofilm formation by Aspergillus fumigatus","volume":"52","author":"S Kaur","year":"2014","journal-title":"Med Mycol"},{"issue":"5","key":"pone.0344286.ref019","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11046-023-00727-z","article-title":"Treatment of invasive aspergillosis: how it\u2019s going, where it\u2019s heading","volume":"188","author":"J Boyer","year":"2023","journal-title":"Mycopathologia"},{"issue":"166","key":"pone.0344286.ref020","doi-asserted-by":"crossref","first-page":"220114","DOI":"10.1183\/16000617.0114-2022","article-title":"Pulmonary aspergillosis: Diagnosis and treatment","volume":"31","author":"F Lamoth","year":"2022","journal-title":"Eur Respir Rev"},{"issue":"12","key":"pone.0344286.ref021","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11908-019-0702-9","article-title":"Antifungal resistance: A concerning trend for the present and future","volume":"21","author":"JA Hendrickson","year":"2019","journal-title":"Curr Infect Dis Rep"},{"issue":"8","key":"pone.0344286.ref022","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1086\/592117","article-title":"Amphotericin B: The higher the dose, the higher the toxicity","volume":"47","author":"AC Pasqualotto","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"8","key":"pone.0344286.ref023","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00399-19","article-title":"Echinocandins for the Treatment of Invasive Aspergillosis: From Laboratory to Bedside","volume":"63","author":"M Aruanno","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"pone.0344286.ref024","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.drudis.2022.04.021","article-title":"Repurposing and optimization of drugs for discovery of novel antifungals","volume":"27","author":"MJ Donlin","year":"2022","journal-title":"Drug Discov Today"},{"issue":"1","key":"pone.0344286.ref025","doi-asserted-by":"crossref","first-page":"12945","DOI":"10.1038\/s41598-019-49425-1","article-title":"Synergistic antifungal interactions of amphotericin B with 4-(5-methyl-1,3,4-thiadiazole-2-yl) benzene-1,3-diol","volume":"9","author":"B Chudzik","year":"2019","journal-title":"Sci Rep"},{"issue":"3","key":"pone.0344286.ref026","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"E De Clercq","year":"2016","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"pone.0344286.ref027","doi-asserted-by":"crossref","first-page":"106906","DOI":"10.1016\/j.ijantimicag.2023.106906","article-title":"Lopinavir and ritonavir act synergistically with azoles against Candida auris in vitro and in a mouse model of disseminated candidiasis","volume":"62","author":"EA Salama","year":"2023","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"pone.0344286.ref028","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1038\/s41598-024-52012-8","article-title":"Enhanced antifungal activity of posaconazole against Candida auris by HIV protease inhibitors, atazanavir and saquinavir","volume":"14","author":"Y Elgammal","year":"2024","journal-title":"Sci Rep"},{"issue":"5","key":"pone.0344286.ref029","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01631-22","article-title":"Atazanavir resensitizes Candida auris to azoles","volume":"67","author":"Y Elgammal","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"pone.0344286.ref030","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00684-20","article-title":"Potent synergistic interactions between lopinavir and azole antifungal drugs against emerging multidrug-resistant candida auris","volume":"65","author":"HE Eldesouky","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"pone.0344286.ref031","doi-asserted-by":"crossref","DOI":"10.1093\/mmy\/myad081","article-title":"Saquinavir potentiates itraconazole\u2019s antifungal activity against multidrug-resistant Candida auris in vitro andin vivo","volume":"61","author":"Y Elgammal","year":"2023","journal-title":"Med Mycol"},{"issue":"5","key":"pone.0344286.ref032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0324080","article-title":"HIV protease inhibitors restore amphotericin B activity against Candida","volume":"20","author":"Y Elgammal","year":"2025","journal-title":"PLoS One"},{"issue":"8","key":"pone.0344286.ref033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0308216","article-title":"Novel combinatorial approach: Harnessing HIV protease inhibitors to enhance amphotericin B\u2019s antifungal efficacy in cryptococcosis","volume":"19","author":"NM Alkashef","year":"2024","journal-title":"PLoS One"},{"issue":"12","key":"pone.0344286.ref034","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0314474","article-title":"Synergistic potential of lopinavir and azole combinational therapy against clinically important Aspergillus species","volume":"19","author":"N Burns","year":"2024","journal-title":"PLoS One"},{"issue":"10","key":"pone.0344286.ref035","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00484-25","article-title":"A screen to identify antifungal antagonists reveals a variety of pharmacotherapies that induce echinocandin tolerance in Candida albicans","volume":"69","author":"P Reitler","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"pone.0344286.ref036","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1177\/2325957416650260","article-title":"Safety and Tolerability of Stribild in the Southeast United States","volume":"15","author":"CB Derrick","year":"2016","journal-title":"J Int Assoc Provid AIDS Care"},{"issue":"2","key":"pone.0344286.ref037","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1177\/0897190017710519","article-title":"A review of the efficacy and safety of Genvoya(R) (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the management of HIV-1 infection","volume":"31","author":"SA Angione","year":"2018","journal-title":"J Pharm Pract"},{"issue":"1","key":"pone.0344286.ref038","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12866-020-1718-x","article-title":"Synergistic effects of vorinostat (SAHA) and azoles against Aspergillus species and their biofilms","volume":"20","author":"B Tu","year":"2020","journal-title":"BMC Microbiol"},{"issue":"4","key":"pone.0344286.ref039","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01458-21","article-title":"Screening of Chemical Libraries for New Antifungal Drugs against Aspergillus fumigatus Reveals Sphingolipids Are Involved in the Mechanism of Action of Miltefosine","volume":"12","author":"TF Dos Reis","year":"2021","journal-title":"mBio"},{"key":"pone.0344286.ref040","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3389\/fimmu.2019.00283","article-title":"LL37 Inhibits Aspergillus fumigatus Infection via Directly Binding to the Fungus and Preventing Excessive Inflammation","volume":"10","author":"X-L Luo","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"pone.0344286.ref041","doi-asserted-by":"crossref","first-page":"18941","DOI":"10.1038\/s41598-019-55379-1","article-title":"Identification of a phenylthiazole small molecule with dual antifungal and antibiofilm activity against candida albicans and candida auris","volume":"9","author":"H Mohammad","year":"2019","journal-title":"Sci Rep"},{"issue":"3","key":"pone.0344286.ref042","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/318483","article-title":"Aspergillosis case-fatality rate: Systematic review of the literature","volume":"32","author":"SJ Lin","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"8","key":"pone.0344286.ref043","article-title":"Invasive pulmonary aspergillosis real-world outcomes: Clinical features and risk factors associated with increased mortality","volume":"61","author":"AF Henao-Mart\u00ednez","year":"2023","journal-title":"Med Mycol"},{"issue":"4","key":"pone.0344286.ref044","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1183\/09031936.02.00256102","article-title":"Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients","volume":"19","author":"F Reichenberger","year":"2002","journal-title":"Eur Respir J"},{"issue":"8","key":"pone.0344286.ref045","doi-asserted-by":"crossref","DOI":"10.3390\/jof11080555","article-title":"Emerging risk factors for invasive pulmonary aspergillosis: A narrative review","volume":"11","author":"A Elkhapery","year":"2025","journal-title":"Journal of Fungi"},{"issue":"5","key":"pone.0344286.ref046","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.medmal.2019.07.014","article-title":"Azole-resistant Aspergillus fumigatus: A global phenomenon originating in the environment?","volume":"50","author":"A Jeanvoine","year":"2020","journal-title":"Med Mal Infect"},{"key":"pone.0344286.ref047","doi-asserted-by":"crossref","DOI":"10.1080\/13693780600826715","article-title":"Treatment of invasive aspergillosis: Polyenes, echinocandins, or azoles?","volume":"44","author":"TF Patterson","year":"2006","journal-title":"Med Mycol"},{"issue":"2","key":"pone.0344286.ref048","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3390\/pathogens14020126","article-title":"Novel strategies for preventing fungal infections-outline","volume":"14","author":"DJ Agbadamashi","year":"2025","journal-title":"Pathogens"},{"key":"pone.0344286.ref049","article-title":"Newer combination antifungal therapies for invasive aspergillosis","author":"WJ Steinbach","year":"2011","journal-title":"Med Mycol"},{"issue":"11","key":"pone.0344286.ref050","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae646","article-title":"CAF to the rescue! potential and challenges of combination antifungal therapy for reducing morbidity and mortality in hospitalized patients with serious fungal infections","volume":"11","author":"SE Jacobs","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"pone.0344286.ref051","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: a randomized trial","volume":"162","author":"KA Marr","year":"2015","journal-title":"Ann Intern Med"},{"issue":"5","key":"pone.0344286.ref052","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3390\/ph14050488","article-title":"Drug Repurposing in Medical Mycology: Identification of Compounds as Potential Antifungals to Overcome the Emergence of Multidrug-Resistant Fungi","volume":"14","author":"L Peyclit","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"pone.0344286.ref053","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/mmy\/myw060","article-title":"The anti-Aspergillus drug pipeline: Is the glass half full or empty?","volume":"55","author":"N Osherov","year":"2017","journal-title":"Med Mycol"},{"issue":"4","key":"pone.0344286.ref054","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/11584570-000000000-00000","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir","volume":"50","author":"S Ramanathan","year":"2011","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"pone.0344286.ref055","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1177\/1060028017717018","article-title":"Cobicistat versus ritonavir: similar pharmacokinetic enhancers but some important differences","volume":"51","author":"A Tseng","year":"2017","journal-title":"Ann Pharmacother"},{"issue":"9","key":"pone.0344286.ref056","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.clinthera.2015.07.022","article-title":"Cobicistat: Review of a pharmacokinetic enhancer for HIV infection","volume":"37","author":"EM Sherman","year":"2015","journal-title":"Clin Ther"},{"key":"pone.0344286.ref057","article-title":"Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial","author":"JJ Eron","year":"2018","journal-title":"Lancet HIV"},{"issue":"4","key":"pone.0344286.ref058","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3390\/pathogens4040883","article-title":"Calcineurin orchestrates hyphal growth, septation, drug resistance and pathogenesis of Aspergillus fumigatus: Where do we go from here?","volume":"4","author":"PR Juvvadi","year":"2015","journal-title":"Pathogens"},{"issue":"5","key":"pone.0344286.ref059","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011152","article-title":"Aspergillus fumigatus transcription factor ZfpA regulates hyphal development and alters susceptibility to antifungals and neutrophil killing during infection","volume":"19","author":"TJ Schoen","year":"2023","journal-title":"PLoS Pathog"},{"issue":"1","key":"pone.0344286.ref060","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3390\/jof8010048","article-title":"Growth of Aspergillus fumigatus in Biofilms in Comparison to Candida albicans","volume":"8","author":"E Subroto","year":"2022","journal-title":"J Fungi (Basel)"},{"issue":"3","key":"pone.0344286.ref061","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3390\/jof11030236","article-title":"The hidden fortress: A comprehensive review of fungal biofilms with emphasis on cryptococcus neoformans","volume":"11","author":"HM Pruitt","year":"2025","journal-title":"J Fungi (Basel)"},{"issue":"3","key":"pone.0344286.ref062","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.MB-0007-2014","article-title":"From biology to drug development: new approaches to combat the threat of fungal biofilms","volume":"3","author":"CG Pierce","year":"2015","journal-title":"Microbiol Spectr"},{"issue":"14","key":"pone.0344286.ref063","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1056\/NEJMoa1110404","article-title":"Combination antifungal therapy for cryptococcal meningitis","volume":"368","author":"JN Day","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0344286.ref064","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02086-23","article-title":"Efficacy of the combination of amphotericin B and echinocandins against Candida auris in vitro and in the Caenorhabditis elegans host model","volume":"12","author":"A Hernando-Ortiz","year":"2024","journal-title":"Microbiol Spectr"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0344286","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T17:30:42Z","timestamp":1774459842000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0344286"}},"subtitle":[],"editor":[{"given":"Aijaz","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":64,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0344286","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]}}}